Temprian Therapeutics

Temprian uses DNA coding to treat and possibly cure vitilig...


Private Fundraise

This company may be interested in raising funds from accredited investors. You must Request Access to see more information about this company.

Request Access 9

Vitiligo Has Physical
& Emotional Effects

Between 35 and 70 million people worldwide suffer from vitiligo.

This depigmentation disease carries a negative stigma and causes great hardship for those affected, including significant social and professional implications.

Remedies are few and far between, with management strategies including makeup, bleaching, skin transplants, corticosteroids and UV therapy.

A better, safe and effective treatment option is needed.

Temprian Therapeutics: Fast Facts

Temprian Therapeutics is a biotech spin-off from Northwestern University.

The company's technology is based on over 25 years of research in the areas of gene therapies, autoimmune diseases and dermatology from the labs of Professor Caroline Le Poole.  The lead program is a platform technology to treat autoimmune diseases such as vitiligo.

Temprian Reverses
the Effects of Vitiligo 

Temprian Therapeutics has developed a new way to treat vitiligo.

By directly injecting into the skin, DNA  coding for a modified heat shock protein HSP70i, we stop the autoimmune response and reverse vitiligo.

The slightly modified protein will be introduced into the skin by a series of needle-free DNA injections.

Laboratory research with vitiligo disease models show that mice and swine respond well to four weekly                                                                treatments, to initiate the path to recovery.

How It Works

Traction & Accomplishments

PRODUCT DEVELOPMENTBy year 2000, Dr. Caroline Le Poole demonstrated that vitiligo is an autoimmune disease. Since then, the lab has deciphered the mechanism of action, identified the specific protein that drives the disease, created a modified version of that protein (modified HSP70i), demonstrated proof of concept in mice, swine and human skin tissue, manufactured bench grade version of product,  and met with the FDA to receive confirmation and guidance for plans to gain market approval.

We have > 100,000 Facebook followers, a strong worldwide network of professional connections, and our inventor received a lifetime award from the International Federation of Pigment Cell Societies 2020.

The drug is manufactured by Aldevron and we are in discussions with several potential partners. We are backed by Northwestern University.

NOV 2020: In-licensure of US Patent: MUTANT HSP70i TO PREVENT AUTOIMMUNE DISEASE; MAY 2020: IP Strategy developed with Polsinelli; Projected Regulatory Exclusivity: US/12 yrs., EU & Canada/8 yrs. and China/6 yrs.  US PATENT MUTANT HSP70i TO PREVENT AUTOIMMUNE DISEASE; Protection through March 2033:

Meet The Team

CEO / Co-founder Kettil Cedercreutz, MSME, PhD, seasoned executive, with solid experience in the development of successful products and programs.

CSO / Co-founder Caroline Le Poole, PhD is a Northwestern Professor in Dermatology, Microbiology and Immunology. She is a thought leader in the field, holding a groundbreaking understanding of vitiligo as an autoimmune disease.

CFO Paul Burton, JD, MBA is a seasoned investment banker who started his career at the Salomon Brothers. Today he is a serial entrepreneur focusing on pharmaceutical drug and product development.

Clinical Development Advisor Pearl Grimes, MD  Owner and Director of The Vitiligo and Pigmentation  Institute of Southern California, Clinical Professor of Dermatology at UCLA.

Clinical Development Advisor S. Walker, M.D., Ph.D is a board-certified dermatologist who has played a key role in the development of Tazorac®, Botox® Cosmetic, Juvederm™, Hylaform® and Captique®.

Director of Regulatory Compliance Mukesh Kumar, PhD has experience in guiding 50+ products through the IND process.

CIO Prof. John D. Nieland, Strategic Advising, PhD is a serial biotech startup entrepreneur specialized in platform development and HSP70i.

The Business Plan area is locked. You must Request Access to this company to see more information including the Business Plan.

Request Access


No updates yet.


No backers yet.

Quick Signup TBD

You must have an account to do this!

the startups.com platform

Copyright © 2019 Startups.com. All rights reserved.

Fundable is a software as a service funding platform. Fundable is not a registered broker-dealer and does not offer investment advice or advise on the raising of capital through securities offerings. Fundable does not recommend or otherwise suggest that any investor make an investment in a particular company, or that any company offer securities to a particular investor. Fundable takes no part in the negotiation or execution of transactions for the purchase or sale of securities, and at no time has possession of funds or securities. No securities transactions are executed or negotiated on or through the Fundable platform. Fundable receives no compensation in connection with the purchase or sale of securities.